Physician profile
Robin Fintel
NPI 1023083250
$5,649.60
in general payments reported to CMS, 2019-2025
15 companies · $666 in 2025
The $666 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $74.96 · 2021: $390 · 2022: $493 · 2023: $2,612 · 2024: $778 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,056 · Consulting Fee: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,056.48 |
| Consulting Fee | $2,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,022.66 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $685.24 | 2019-2024 | Trulance, Xifaxan, Plenvu |
| Janssen Pharmaceuticals, INC | $529.01 | 2019-2023 | Xarelto |
| Phathom Pharmaceuticals, INC. | $521.92 | 2024-2025 | Voquezna |
| Pfizer INC. | $397.11 | 2019-2025 | |
| Janssen Biotech, INC. | $351.33 | 2019-2025 | Tremfya, Stelara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $333.05 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $246.89 | 2021-2024 | Wainua |
| Kowa Pharmaceuticals America, INC. | $131.61 | 2019 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| Merck Sharp & Dohme LLC | $121.58 | 2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $56.77 | 2019 | |
| Romark Laboratories, Lc | $52.05 | 2019-2020 | |
| Madrigal Pharmaceuticals | $42.19 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $33.19 | 2023 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Fintel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.